NCT03254810View on ClinicalTrials.gov

Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

July 17, 2018

Study Completion Date

July 17, 2018

Conditions
Arthritis, Rheumatoid
Interventions
BIOLOGICAL

SYN060

a single subcutaneous 0.57 mg/kg dose of SYN060

BIOLOGICAL

Adalimumab North American source

a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source

BIOLOGICAL

Adalimumab European source

a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from European source

Trial Locations (1)

3004

Nucleus Network, Melbourne

All Listed Sponsors
lead

Synermore Biologics Co., Ltd.

INDUSTRY

NCT03254810 - Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter